Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 5.92% in its latest trading session, closing at $8.27, which underperformed compared to the S&P 500's loss of 0.51% [1] - Over the past month, the company's shares have decreased by 4.14%, lagging behind the Medical sector's gain of 3.1% and the S&P 500's increase of 0.93% [1] Upcoming Earnings - Analysts anticipate that Ginkgo Bioworks will report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1%. Revenue is projected to be $37 million, reflecting a 15.62% decline from the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing changes of +42.66% in earnings and 0% in revenue compared to the previous year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Ginkgo Bioworks are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Ginkgo Bioworks a rank of 3 (Hold), with the consensus EPS estimate remaining steady over the past month [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]